Cheon Younghoon, Park Jaewoo, Joe Keun-Ho, Kim Dai-Jin
Department of Psychiatry, Incheon Chamsarang Hospital, Seojin Medical Research Institute, Incheon, Korea.
Int J Neuropsychopharmacol. 2008 Nov;11(7):971-83. doi: 10.1017/S1461145708008663. Epub 2008 Mar 17.
There is compelling evidence that alcohol-induced neurotoxicity is related to glutamate excitotoxicity. It was hypothesized that the low-affinity NMDA receptor antagonist memantine would improve the cognitive function of patients with alcoholic dementia. The aim of this study was to test this hypothesis and to evaluate the effect of memantine on the cognitive improvement of patients with alcohol-related dementia (ARD). The study was designed as a 12-wk open-label study investigating the efficacy of 20 mg memantine, a low-affinity NMDA receptor antagonist, as a treatment for cognitive and behavioural problems in 19 patients with probable ARD according to the criteria for ARD proposed by Oslin and colleagues. The CERAD-K (Consortium to Establish a Registry for Alzheimer's Disease - Korean version) and several clinical assessment scales were completed before and after the 12-wk memantine treatment period. Significant improvements in the mean scores from baseline to final assessment were observed in the Global Deterioration Scale (p<0.05), Brief Psychiatric Rating Scale (p<0.01), Geriatric Quality of Life - Dementia scale (p<0.01) and Neuropsychiatric Inventory (p<0.01) at the end of week 12. The CERAD-K subscales of word list recall (p<0.05), word list recognition (p<0.05), time orientation (p<0.01), drawing an interlocking pentagon (p<0.05), and the total MMSE-K (Mini Mental State Examination - Korean version) scores (p<0.01) of the patients all showed significant improvement following the memantine trial. In this open-label study, patients with ARD treated with 20 mg/d memantine for 12 wk showed improvement on global cognition, quality of life and behavioural symptoms. The result of this study suggests the possible usefulness of memantine for the treatment of ARD. As this was an open-label study, the possibility that participants improved cognitively on their own due to protracted abstinence from alcohol cannot be discounted.
有令人信服的证据表明,酒精诱导的神经毒性与谷氨酸兴奋性毒性有关。据推测,低亲和力N-甲基-D-天冬氨酸(NMDA)受体拮抗剂美金刚可改善酒精性痴呆患者的认知功能。本研究的目的是验证这一假设,并评估美金刚对酒精相关痴呆(ARD)患者认知改善的效果。该研究设计为一项为期12周的开放标签研究,根据奥斯林及其同事提出的ARD标准,调查20mg美金刚(一种低亲和力NMDA受体拮抗剂)对19例可能患有ARD患者的认知和行为问题的治疗效果。在为期12周的美金刚治疗期前后,完成了阿尔茨海默病注册协会-韩国版(CERAD-K)以及几个临床评估量表。在第12周结束时,全球衰退量表(p<0.05)、简明精神病评定量表(p<0.01)、老年痴呆生活质量量表(p<0.01)和神经精神科问卷(p<0.01)的平均得分从基线到最终评估均有显著改善。患者的CERAD-K子量表中的单词列表回忆(p<0.05)、单词列表识别(p<0.05)、时间定向(p<0.01)、绘制一个连锁五边形(p<0.05)以及总简易精神状态检查表-韩国版(MMSE-K)得分(p<0.01)在美金刚试验后均显示出显著改善。在这项开放标签研究中,每天服用20mg美金刚治疗12周的ARD患者在整体认知、生活质量和行为症状方面均有改善。本研究结果表明美金刚治疗ARD可能有效。由于这是一项开放标签研究,不能排除参与者因长期戒酒而自身认知改善的可能性。